Immunovant's Batoclimab Fails Phase 3 TED Trial; Roivant Expands Brepocitinib Program into New LPP Study
ROIV has more than doubled off its 52-week low of $8.73.
Summary
Roivant announced mixed clinical updates, with Immunovant's batoclimab failing to meet its primary endpoint in two Phase 3 studies for Thyroid Eye Disease (TED). This represents a significant setback for Immunovant (IMVT) and a material negative for Roivant (ROIV) due to its substantial investment in the company, eliminating a potential late-stage revenue stream for this indication. Separately, Roivant's Priovant subsidiary expanded its brepocitinib development program into a new Phase 2b/3 trial for Lichen Planopilaris (LPP), an orphan condition with no FDA-approved therapies. While the brepocitinib expansion is a positive pipeline development, the definitive Phase 3 failure for batoclimab is a more immediate and impactful negative catalyst. Investors will now monitor Immunovant's revised development plans for batoclimab and the progress of its other FcRn blocker, IMVT-1402, as well as the upcoming PDUFA date for brepocitinib in dermatomyositis in Q3 2026.
At the time of this announcement, ROIV was trading at $27.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $19.9B. The 52-week trading range was $8.73 to $30.33. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.